Gad Cotter

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

John R. Teerlink, Gad Cotter, Beth A. Davison et al. · The Lancet · 2012 · 896 citations

Heart Failure, Cardiac Anaesthesia, Cardiogenic Shock +10

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Alexandre Mebazaa, Beth A. Davison, Ovidiu Chioncel et al. · The Lancet · 2022 · 882 citations · Full text

Heart Failure, Structural Heart Disease, Cardiovascular Disease +8

Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry

Rupert Fincke, Judith S. Hochman, April M. Lowe et al. · Journal of the American College of Cardiology · 2004 · 620 citations

Cardiac Power, Cardiogenic Shock, Cardiovascular Disease +7

Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema

Gad Cotter, Einat Metzkor, Edo Kaluski et al. · The Lancet · 1998 · 590 citations

High-dose Isosorbide Dinitrate, Severe Pulmonary Oedema, Pulmonary Pharmacology +6

The Causes, Treatment, and Outcome of Acute Heart Failure in 1006 Africans From 9 Countries

Albertino Damasceno, Bongani M. Mayosi, Mahmoud U. Sani et al. · Archives of Internal Medicine · 2012 · 511 citations